{"protocolSection":{"identificationModule":{"nctId":"NCT05227521","orgStudyIdInfo":{"id":"S66123"},"secondaryIdInfos":[{"id":"1153320N","type":"OTHER_GRANT","domain":"Research Foundation - Flanders (FWO)"}],"organization":{"fullName":"KU Leuven","class":"OTHER"},"briefTitle":"Feasibility of the Adapted H-GRASP Feedback Program in the Chronic Phase Post Stroke.","officialTitle":"The Feasibility of the Adapted H-GRASP Feedback Program for Perceived and Daily Life UL Activity in Patients With Good Observed But Low Perceived Activity in the Chronic Phase Post Stroke: a Pilot Study."},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-01-31","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-06-25","type":"ACTUAL"},"completionDateStruct":{"date":"2023-06-25","type":"ACTUAL"},"studyFirstSubmitDate":"2022-01-14","studyFirstSubmitQcDate":"2022-01-26","studyFirstPostDateStruct":{"date":"2022-02-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-30","lastUpdatePostDateStruct":{"date":"2023-07-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Prof Geert Verheyden","investigatorTitle":"Professor","investigatorAffiliation":"KU Leuven"},"leadSponsor":{"name":"KU Leuven","class":"OTHER"},"collaborators":[{"name":"Universitaire Ziekenhuizen KU Leuven","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"In a recent cross-sectional study, it was shown that people with a good observed upper limb (UL) motor function but low perceived UL activity show a reduced daily-life UL activity. The investigators will now investigate the feasibility of a phone-monitored home exercise and feedback program for the UL following stroke and the preliminary effects on the perceived UL activity and actual daily-life UL activity for participants with good observed UL motor function but low perceived UL activity in the chronic phase post-stroke."},"conditionsModule":{"conditions":["Stroke"],"keywords":["upper limb","daily life activity","home-based exercise program","feedback","perceived activity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":19,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"AH-GRASP feedback intervention group","type":"EXPERIMENTAL","description":"All study participants will receive the AH-GRASP feedback intervention.","interventionNames":["Behavioral: Adapted H-GRASP feedback program"]}],"interventions":[{"type":"BEHAVIORAL","name":"Adapted H-GRASP feedback program","description":"Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback","armGroupLabels":["AH-GRASP feedback intervention group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Recruitment rate","description":"% of individuals who were eligible and agreed to participate","timeFrame":"45 days (post-intervention)"},{"measure":"Retention rate","description":"% of participants who completed the intervention","timeFrame":"45 days (post-intervention)"},{"measure":"Adherence to the intervention protocol","description":"% of participants who achieved 12 hours of average weekly exercise","timeFrame":"45 days (post-intervention)"},{"measure":"Safety","description":"# of participants with increased pain while performing exercises as measured by visual analogue scale","timeFrame":"45 days (post-intervention)"},{"measure":"Activity ratio","description":"Contribution to the activity of one upper limb (UL) versus the other: hours of activity of the affected divided by the unaffected UL","timeFrame":"Day 1 (enrolment)"},{"measure":"Activity ratio","description":"Contribution to the activity of one upper limb (UL) versus the other: hours of activity of the affected divided by the unaffected UL","timeFrame":"Day 17 (baseline)"},{"measure":"Activity ratio","description":"Contribution to the activity of one upper limb (UL) versus the other: hours of activity of the affected divided by the unaffected UL","timeFrame":"45 days (post-intervention)"},{"measure":"Hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand)","description":"Perceived activity of the affected UL. Minimum 0 - maximum 100; higher scores mean better outcome.","timeFrame":"Day 1 (enrolment)"},{"measure":"Hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand)","description":"Perceived activity of the affected UL. Minimum 0 - maximum 100; higher scores mean better outcome.","timeFrame":"Day 17 (baseline)"},{"measure":"Hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand)","description":"Perceived activity of the affected UL. Minimum 0 - maximum 100; higher scores mean better outcome.","timeFrame":"45 days (post-intervention)"}],"secondaryOutcomes":[{"measure":"Fugl-Meyer motor assessment - upper extremity (FMA-UE)","description":"Observed motor function of the affected UL (shoulder, arm, wrist, hand, and fingers)","timeFrame":"Day 1 (enrolment), day 17 (baseline), 45 days (post-intervention)"},{"measure":"Action Research Arm Test (ARAT)","description":"Grasp, grip, pinch and gross movement of the affected UL","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"Motor Activity Log - 14 Item Version Amount Of Use (MAL-14 AOU)","description":"Patient-reported amount of UL use in daily life","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"Motor Activity Log - 14 Item Version Quality Of Movement (MAL-14 QOM)","description":"Patient-reported quality of UL use in daily life","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"Erasmus modified Nottingham Sensory Assessment (Em-NSA)","description":"Sensory assessment of the UL","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"simplified modified Rankin Scale questionnaire (smRSq)","description":"Global disability. Minimum 0 - maximum 5; higher scores mean worse outcome.","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"Hospital Anxiety and Depression Scale (HADS)","description":"Symptoms of anxiety and depression. Minimum 0 - maximum 42; higher scores mean worse outcome.","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"Confidence in Arm and Hand Movement Scale (CAHM)","description":"Perceived self-efficacy in performing tasks with the affected UL. Minimum 0 - maximum 100; higher scores mean better outcome.","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"Visual Analogue Scale (VAS)","description":"Pain intensity in the affected UL from 0 (no pain) to 10 (extreme). Minimum 0, maximum 10, higher scores mean worse outcome.","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"EuroQol Five Dimensions Five Levels Questionnaire (EQ-5D-5L)","description":"Health-related quality of life. Minimum 0, maximum 100, higher scores mean better outcome.","timeFrame":"Day 17 (baseline), 45 days (post-intervention)"},{"measure":"Hours of UL activity","description":"Sum of all seconds recorded when the activity count was nonzero and converted to hours","timeFrame":"Day 1 (enrolment), day 17 (baseline), 45 days (post-intervention)"},{"measure":"Bilateral magnitude","description":"Intensity of the movement: sum of the vector magnitude from the two ULs","timeFrame":"Day 1 (enrolment), day 17 (baseline), 45 days (post-intervention)"},{"measure":"Magnitude ratio","description":"Contribution to the activity of one limb versus the other: natural log of the vector magnitude of the affected UL divided by the vector magnitude of the unaffected UL, whereby values greater than and less than -7 were replaced by 7 and -7, respectively, to categorize single limb movement.","timeFrame":"Day 1 (enrolment), day 17 (baseline), 45 days (post-intervention)"},{"measure":"Density plot","description":"Graphical representation of accelerometry data from both ULs","timeFrame":"Day 1 (enrolment), day 17 (baseline), 45 days (post-intervention)"}],"otherOutcomes":[{"measure":"Demographics","description":"Participant demography","timeFrame":"Day 1 (enrolment)"},{"measure":"Stroke event data","description":"Disease characteristics","timeFrame":"Day 1 (enrolment)"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"Neurological impairments. Minimum 0, maximum 42, higher scores mean worse outcome.","timeFrame":"Day 1 (enrolment)"},{"measure":"Edinburgh Handedness Inventory (EHI)","description":"Handedness","timeFrame":"Day 1 (enrolment)"},{"measure":"Montreal Cognitive Assessment (MoCA)","description":"Cognitive function","timeFrame":"Day 1 (enrolment)"},{"measure":"Apples Test","description":"Visuospatial neglect","timeFrame":"Day 1 (enrolment)"},{"measure":"Barthel Index (BI)","description":"Performance in activities of daily living","timeFrame":"Day 1 (enrolment)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. First-ever unilateral, supratentorial stroke, as defined by the American Heart Association/American Stroke Association\n3. Minimum six months after stroke\n4. Living in the community\n5. ≥18 years old\n6. Good observed UL motor function but low perceived UL activity. Good observed UL motor function is defined as a score \\>50/66 on the Fugl-Meyer Assessment-Upper Extremity (FMA-UE). Low perceived UL activity is defined as a score ≤75/100 on the hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand).\n\nExclusion Criteria:\n\n1. Other neurological condition than stroke\n2. Musculoskeletal disorder that affects UL use\n3. No informed consent\n4. Participation in an interventional Study with an investigational medicinal product (IMP) or device","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Geert Verheyden, Professor","affiliation":"KU Leuven","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Private physiotherapy practices","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}